Search
Medicaid Monitor
Saturday, November 21, 2026 · Updated Fri 12:06 PM MT · 52 stories on Friday, November 20
Medicaid Monitor Pro
Sat, Nov 21 · 52 stories on Friday, November 20PRO
← All stories
IndustryMay 28, 2026

Trump Drug Pricing Deals Face First Test as New Launches Reveal List Prices

Seventeen pharmaceutical manufacturers that signed most-favored-nation pricing agreements with the Trump administration are beginning to launch new products, providing the first public test of whether these voluntary commitments will constrain launch prices. The agreements, which pledge U.S. list prices will not exceed prices in other developed nations, lack formal enforcement mechanisms and apply only to new products launched after signing. For Medicaid managed care organizations, these launches will reveal whether rebate strategies and supplemental rebate negotiations need adjustment, particularly if launch prices come in lower than historical benchmarks would predict.

Pharmacy · Managed Care

Read the full article at statnews.com →
Share this briefing

You might also like

← All stories

Get the daily briefing.